Integrated.
Systems.
Solutions.
Thinking.

Merrimack is committed to the fight against cancer. We are a science-driven community seeking to understand the complexity of the disease, engineer better solutions and deliver life-saving results for patients.

The Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval

MM-302 is Merrimack's wholly owned, novel antibody-drug conjugated liposomal doxorubicin that targets and binds to HER2, a protein that when overexpressed can lead to the development and aggressive progression of breast cancer.

Learn More

Merrimack Identifies Heregulin as a Patient Response Biomarker for MM-121 Across Multiple Cancers

The expression of heregulin (HRG), the principal ligand that binds to and activates the ErbB3 receptor, has been found to be associated with poor response to standard of care therapy for patients with platinum-resistant ovarian cancer, ER/PR+ HER2- breast cancer and EGFR wild-type non-small cell lung cancer. Results from three Phase 2 studies indicate that 30-50 percent of patients most at risk of progession may benefit from MM-121, which is designed to block heregulin binding to ErbB3.

Learn More

Breaking down the science of systems biology

Learn More

Baxter and Merrimack Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398

Learn More

Our Heroes

Merrimack is proud to partner with The Pancreatic Cancer Action Network to raise awareness and research efforts for pancreatic cancer. PanCan is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. 

Learn More

MM-398 Achieves Primary Endpoint in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer

MM-398 in combination with 5-fluorouracil and leucovorin demonstrates a statistically significant advantage in overall survival compared to the control arm, in patients with metastatic pancreatic cancer who have been previously treated with gemcitabine.

Read more about the trial results here.

Learn More